Reperfusion therapy for acute ischemic stroke in older people: An observational real-life study.
ischemic stroke
older adults
outcome
thrombectomy
thrombolysis
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
17
06
2021
received:
16
04
2021
accepted:
26
06
2021
pubmed:
11
8
2021
medline:
29
12
2021
entrez:
10
8
2021
Statut:
ppublish
Résumé
While randomized clinical trials have shown the benefit of thrombolysis and endovascular thrombectomy (EVT) in patients with acute ischemic stroke (AIS), we aimed to describe in a real-life study the differences between older (>80 years old) and younger patients treated for AIS. Thousand patients treated with thrombolysis and/or EVT were consecutively included in a prospective monocentric database (admitted from December 2015 to May 2019 in our comprehensive stroke center). Demographic data with detailed history, baseline physical examinations and treatments, laboratory and imaging data, prestroke functional status, and outcome 3 months after stroke were analyzed. Older patients (n = 357) had more baseline comorbidities and lower levels of prestroke independence (modified Rankin scale ≤2; 67.2% vs. 96.1%) and more severe strokes (median National Institute of Health Stroke Score [NIHSS] 15 vs. 12; p < 0.001) than younger patients (n = 643). There was no difference in the reperfusion treatments used or treatment timelines. In older patients, good functional status at 3 months was less common (29.7% vs. 61.3%) and mortality was higher (37.1% vs. 11.4%) than in younger patients. Younger age was independently associated with better prognosis (odds ratio [OR] 0.37, 95% confidence interval [CI]: 0.20-0.67; p = 0.001) and lower mortality (OR 4.38, 95% CI: 2.11-9.09; p < 0.001). Among older adults, features associated with good outcome at 3 months were age (OR 0.89, 95% CI: 0.81-0.97; p = 0.01), initial NIHSS (OR 0.89, 95% CI: 0.83-0.94; p < 0.0001), and absence of severe leukoaraiosis, anticoagulant treatment, and symptomatic intracerebral hemorrhage following reperfusion therapy (respectively, OR 0.42, 95% CI: 0.19-0.93; p = 0.03; OR = 0.07, 95% CI: 0.01-0.70; p = 0.02; and OR = 0.07, 95% CI: 0.01-0.61; p = 0.02). Although reperfusion therapy was less successful in older patients, these patients may benefit from acute recanalization despite their age. With an increasing older adult population, high-quality prospective studies are still required to better predict functional outcome and clarify the criteria that would allow better selection of appropriate treatment.
Sections du résumé
BACKGROUND
While randomized clinical trials have shown the benefit of thrombolysis and endovascular thrombectomy (EVT) in patients with acute ischemic stroke (AIS), we aimed to describe in a real-life study the differences between older (>80 years old) and younger patients treated for AIS.
METHODS
Thousand patients treated with thrombolysis and/or EVT were consecutively included in a prospective monocentric database (admitted from December 2015 to May 2019 in our comprehensive stroke center). Demographic data with detailed history, baseline physical examinations and treatments, laboratory and imaging data, prestroke functional status, and outcome 3 months after stroke were analyzed.
RESULTS
Older patients (n = 357) had more baseline comorbidities and lower levels of prestroke independence (modified Rankin scale ≤2; 67.2% vs. 96.1%) and more severe strokes (median National Institute of Health Stroke Score [NIHSS] 15 vs. 12; p < 0.001) than younger patients (n = 643). There was no difference in the reperfusion treatments used or treatment timelines. In older patients, good functional status at 3 months was less common (29.7% vs. 61.3%) and mortality was higher (37.1% vs. 11.4%) than in younger patients. Younger age was independently associated with better prognosis (odds ratio [OR] 0.37, 95% confidence interval [CI]: 0.20-0.67; p = 0.001) and lower mortality (OR 4.38, 95% CI: 2.11-9.09; p < 0.001). Among older adults, features associated with good outcome at 3 months were age (OR 0.89, 95% CI: 0.81-0.97; p = 0.01), initial NIHSS (OR 0.89, 95% CI: 0.83-0.94; p < 0.0001), and absence of severe leukoaraiosis, anticoagulant treatment, and symptomatic intracerebral hemorrhage following reperfusion therapy (respectively, OR 0.42, 95% CI: 0.19-0.93; p = 0.03; OR = 0.07, 95% CI: 0.01-0.70; p = 0.02; and OR = 0.07, 95% CI: 0.01-0.61; p = 0.02).
CONCLUSION
Although reperfusion therapy was less successful in older patients, these patients may benefit from acute recanalization despite their age. With an increasing older adult population, high-quality prospective studies are still required to better predict functional outcome and clarify the criteria that would allow better selection of appropriate treatment.
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3167-3176Informations de copyright
© 2021 The American Geriatrics Society.
Références
Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439-448.
Population Projections 2004-2050. EU25 population rises until 2025, then falls. Eurostat news release 48/2005; April 8, 2005. Accessed October 3, 2016. http://ec.europa.eu/eurostat/web/products-press-releases/-/3-08042005-AP
Bluhmki E, Danays T, Biegert G, Hacke W, Lees KR. Alteplase for acute ischemic stroke in patients aged >80 years: pooled analyses of individual patient data. Stroke. 2020;51:2322-2331. https://doi.org/10.1161/STROKEAHA.119.028396
Béjot Y, Duloquin G, Graber M, Garnier L, Mohr S, Giroud M. Current characteristics and early functional outcome of older stroke patients: a population-based study (Dijon Stroke Registry). Age Ageing. 2021;50:898-905. https://doi.org/10.1093/ageing/afaa192
Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935.
Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
Goyal M, Menon BK, Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723-1731.
Jayaraman MV, McTaggart RA. Endovascular treatment of anterior circulation large vessel occlusion in the elderly. Front Neurol. 2018;8:713. https://doi.org/10.3389/fneur.2017.00713
Hilditch CA, Nicholson P, Murad MH, et al. Endovascular management of acute stroke in the elderly: a systematic review and meta-analysis. Am J Neuroradiol. 2018;39(5):887-891.
Malhotra A, Wu X, Payabvash S, et al. Comparative effectiveness of endovascular thrombectomy in elderly stroke patients. Stroke. 2019;50:963-969.
Calle IA, Portillo JB, Anton-Ladislao A, et al. Clinical outcome of mechanical thrombectomy for stroke in the elderly. J Stroke Cerebrovasc Dis. 2017;26:582-588.
Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials. Stroke. 2007;38:1091-1096.
Venditti L, Chassin O, Ancelet C, et al. Pre-procedural predictive factors of symptomatic intracranial hemorrhage after thrombectomy in stroke. J Neurol. 2021;268:1867-1875. https://doi.org/10.1007/s00415-020-10364-x
Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355:1670-1674.
Fazekas F, Barkhof F, Wahlund LO, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis. 2002;13(suppl 2):31-36.
Ford G, Freemantle N. ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II. Lancet. 1999;353:65; author reply 67-68.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35-41.
European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischaemic stroke endorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J. 2019;4:6-12.
Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611-622.
Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of ≥80 versus <80 years of age-a systematic review across cohort studies. Age Ageing. 2006;35:572-580.
Ford GA, Ahmed N, Azevedo E, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41:2568-2574.
Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry. 2006;77:826-829.
Uyttenboogaart M, Schrijvers EMC, Vroomen PC, De Keyser J, Luijckx G-J. Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age Ageing. 2007;36:577-579.
Alawieh A, Chatterjee A, Feng W, et al. Thrombectomy for acute ischemic stroke in the elderly: a “real world” experience. J Neurointerv Surg. 2018;10:1209-1217.
Alawieh A, Starke RM, Chatterjee AR, et al. Outcomes of endovascular thrombectomy in the elderly: a “real-world” multicenter study. J Neurointerv Surg. 2019;11:545-553.
Chandra Ronil V, Leslie-Mazwi Thabele M, Oh Daniel C, et al. Elderly patients are at higher risk for poor outcomes after intra-arterial therapy. Stroke. 2012;43:2356-2361.
Duffis EJ, He W, Prestigiacomo CJ, Gandhi CD. Endovascular treatment for acute ischemic stroke in octogenarians compared with younger patients: a meta-analysis. Int J Stroke. 2014;9:308-312.
Groot AE, Treurniet KM, Jansen IGH, et al. Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN registry. Neurology. 2020;95(2):e131-e139. https://doi.org/10.1212/WNL.0000000000009764
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
Forti P, Maioli F, Procaccianti G, et al. Independent predictors of ischemic stroke in the elderly: prospective data from a stroke unit. Neurology. 2013;80:29-38.
Luijten SPR, Bos D, Compagne KCJ, et al. Association of white matter lesions and outcome after endovascular stroke treatment. Neurology. 2021;96:e333-e342.
Fujita K, Tanaka K, Yamagami H, et al. Outcomes of large vessel occlusion stroke in patients aged ≥90years. Stroke. 2021;52:1561-1569. https://doi.org/10.1161/STROKEAHA.120.031386
Sharobeam A, Cordato DJ, Manning N, Cheung A, Wenderoth J, Cappelen-Smith C. Functional outcomes at 90 days in octogenarians undergoing thrombectomy for acute ischemic stroke: a prospective cohort study and meta-analysis. Front Neurol. 2019;10:254.
Tsivgoulis G, Kargiotis O, De Marchis G, et al. Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence. Ther Adv Neurol Disord. 2021;14:1756286421997368. https://doi.org/10.1177/1756286421997368
Berge E, Whiteley W, Audebert H, De Marchis GM, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I-LXII. https://doi.org/10.1177/2396987321989865